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Abstract
Existing data suggest that NF-kappaB signaling is a key regulator of cancer-induced skeletal muscle wasting. However,
identification of the components of this signaling pathway and of the NF-kB transcription factors that regulate wasting is far
from complete. In muscles of C26 tumor bearing mice, overexpression of dominant negative (d.n.) IKKb blocked muscle
wasting by 69% and the IkBa-super repressor blocked wasting by 41%. In contrast, overexpression of d.n. IKKa or d.n. NIK
did not block C26-induced wasting. Surprisingly, overexpression of d.n. p65 or d.n. c-Rel did not significantly affect muscle
wasting. Genome-wide mRNA expression arrays showed upregulation of many genes previously implicated in muscle
atrophy. To test if these upregulated genes were direct targets of NF-kB transcription factors, we compared genome-wide
p65 binding to DNA in control and cachectic muscle using ChIP-sequencing. Bioinformatic analysis of ChIP-sequencing data
from control and C26 muscles showed very little p65 binding to genes in cachexia and little to suggest that upregulated
p65 binding influences the gene expression associated with muscle based cachexia. The p65 ChIP-seq data are consistent
with our finding of no significant change in protein binding to an NF-kB oligonucleotide in a gel shift assay, no activation of
a NF-kB-dependent reporter, and no effect of d.n.p65 overexpression in muscles of tumor bearing mice. Taken together,
these data support the idea that although inhibition of IkBa, and particularly IKKb, blocks cancer-induced wasting, the
alternative NF-kB signaling pathway is not required. In addition, the downstream NF-kB transcription factors, p65 and c-Rel
do not appear to regulate the transcriptional changes induced by the C26 tumor. These data are consistent with the
growing body of literature showing that there are NF-kB-independent substrates of IKKb and IkBa that regulate
physiological processes.
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Introduction
Cachexia is a metabolic condition associated with many chronic
diseases and it is characterized by the severe wasting of skeletal
muscle and adipose tissue which cannot be reversed by increasing
caloric intake [1]. Cancer cachexia is seen in the majority of
advanced cancers but it is most commonly seen in cancers of the
lung and upper GI tract [1]. Cancer patients with cachexia have a
lower quality of life due to compromised immune function, insulin
resistance, weakness, and fatigue [2]. Patients with even mild
cachexia cannot tolerate chemotherapy treatment, which further
exacerbates their illness [3]. Cachexia is estimated to contribute to
the deaths of approximately 30% of cancer patients [4]. For all the
seriousness of this affliction, treatments remain palliative. Since the
more severe consequences of cachexia seem to reside with skeletal
muscle loss [1], developing a better understanding of the cellular
signaling mechanisms and gene regulation in muscle could yield
novel therapeutic strategies for treatment of this condition.
Research on different types of cancer has suggested a role for
NF-kB signaling and NF-kB transcriptional regulation in muscle
wasting [5,6,7]. Inhibition of the classical NF-kB pathway, by
overexpression of the IkappaBalpha super repressor (IkBaSR),
blocked muscle wasting in Lewis lung carcinoma (LLC) tumor-
bearing mice by 50% [5]. The prototypical NF-kB transcription
factor, p65 (Rel A), showed increased binding in an ELISA-based
NF-kB oligonucleotide assay in muscle from mice with LLC. The
increased binding was reversed when IkBaSR was overexpressed
in muscle, suggesting that p65 is a NF-kB transcription factor
involved in muscle wasting due to cancer, at least in mice with
LLC [5]. Phosphorylation of p65 at Serine 536, thought to
increase transcriptional activity, is increased in muscle from C26
tumor bearing mice [6] and in muscle from humans with
pancreatic cancer [8]. On the other hand, some results on the
role of NF-kB transcription factors in cachexia have been
equivocal. For instance, gel shift assays showed small increases
in binding of transcription factors to an NF-kB oligonucleotide in
muscles from C26 tumor bearing mice [6,9], and in another study
there was no increase in protein binding to an NF-kB
oligonucleotide in cachectic rats with Yoshida ascites hepatoma
[10]. It is possible that different types of cancer induce muscle
wasting via different cellular mechanisms. Nevertheless, only one
NF-kB signaling protein (IkBa) and one NF-kB transcription
factor (p65) have been studied in cancer-induced muscle wasting,
and, we do not know the atrophy inducing genes that are targeted
by NF-kB transcription factors.
The purpose of the present study was to identify the known
mammalian NF-kB signaling proteins and NF-kB transcription
factors that regulate muscle wasting due to cancer. A second
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purpose was to identify the NF-kB target genes on a genome-wide
level in order to determine if an NF-kB transcriptional network
regulates cancer-induced muscle wasting. We tested whether NF-
kB signaling proteins are required for muscle wasting by
overexpressing dominant negative (d.n.) forms of upstream NF-
kB kinases. These are the inhibitor of kappaB kinase alpha
(IKKa), IKKb, and the NF-kB inducing kinase (NIK). The role of
IkBa was tested by overexpression of a trans-dominant super
repressor form of IkBa (IkBaSR). Whether the NF-kB transcrip-
tion factors Rel A (p65) or c-Rel are required for muscle wasting
was tested by overexpression of d.n. p65 or d.n. c-Rel, respectively.
NF-kB transcription factor binding to a NF-kB oligonucleotide
and NF-kB transcriptional activity of a reporter were measured in
cachectic muscles. To determine if the canonical NF-kB
transcription factor, p65, bound target genes that could be related
to atrophy regulation, we performed ChIP-sequencing in muscle
from control and tumor bearing mice in conjunction with
measurement of global gene expression as a functional measure
of cachexia-mediated gene expression.
This is the first in-depth study on the role of NF-kB signaling
and of NF-kB transcription factors in the regulation of muscle
wasting due to cancer. Although inhibition of IkBa, and
particularly IKKb activity, significantly reversed muscle wasting,
there was no effect on fiber wasting due to inhibition of IKKa or
NIK. Surprisingly, overexpression of dominant negative p65 or
c-Rel showed little or no effect on muscle fiber wasting.
Furthermore, there was no change in NF-kB transcription factor
binding in a gel shift assay or in NF-kB reporter activity.
Importantly, the upregulation of atrophy or cytokine genes found
by gene expression microarrays was not mediated by p65-
containing transcription factors as assessed by ChIP-seq. Our
findings are consistent with those of Cai et al. [5] showing a role
for IkBa in cancer wasting, and for the first time we show that
IKKb is required for the development of cancer cachexia, but
IKKa and NIK are not. Our in-depth analysis of NF-kB signaling
and transcription during cancer cachexia shows that the IKKb is
regulating gene expression by transcription factors other than NF-
kB, at least in skeletal muscle during C26 cancer cachexia. These
results reveal an unexpected but important facet of the regulation
of cancer-induced muscle wasting.
Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Charles River Campus Boston
University Institutional Animal Care and Use Committee
(protocol number: 12-016). All surgery was performed under
ketamine/xylazine anesthesia, and all efforts were made to
minimize suffering. All personnel working with animals have
undergone mandatory IACUC training and yearly review: http://
www.bu.edu/orctraining/animal/lacf/.
Cells
C26 adenocarcinoma cells (National Cancer Institute, Freder-
ick, MD) were plated and maintained at 37uC, 5% CO2 in
Dulbecco’s Modified Eagle Medium, high glucose (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum
(Invitrogen), 1% penicillin-streptomycin (Invitrogen), and 1% L-
glutamine (Invitrogen). Prior to inoculation into mice, C26 cells
were trypsinized and washed twice with phosphate buffered saline
and then re-suspended in a 1:1 solution of 1X PBS and matrigel
(BD Biosciences, San Jose, CA, USA).
Animals
Eight-week-old, male CDF1 mice purchased from Charles
River Laboratories (Wilmington, MA, USA) were used for all
experiments. Mice were treated in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Animals
were maintained on a 12:12 L/D cycle, were housed individually,
and were given access to food and water ad libitum. After three days
of acclimation, animals were randomly assigned to a non-tumor
control group or a C26 tumor-bearing group. Control animals
received an inoculum of 150 mL 16 PBS/matrigel (1:1) subcuta-
neously into the right and left flanks. Tumor-bearing animals
received an inoculum of 5.06105 C26 cells suspended in 150 mL
PBS/matrigel (1:1) injected subcutaneously into the right and left
flanks; this was performed on lightly anesthetized mice (40 mg/kg
ketamine +5 mg/kg xylazine).
Plasmid DNA injection in muscle
Plasmid DNA was isolated using the QIAGEN Endotoxin-Free
Mega Kit as per manufacturer’s instructions. Plasmid DNA was
injected into muscle 10 days following the tumor inoculations, as
described previously [11]. Briefly, the plasmid DNA was ethanol-
precipitated and re-suspended in 0.45% sterile saline/ddH2O. All
mice receiving surgery were given prophylactic treatments with
0.1 mg/kg Buprenorphine injection prior to surgery. Mice were
anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/kg).
The tibialis anterior (TA) muscles from each animal were injected
with 35 mg of expression plasmid in 25 mL of 0.45% sterile saline
using a 29-gauge insulin syringe. Following the plasmid injection,
muscles were stimulated with a low voltage electrical current using
two-paddle electrodes [12] that delivered 6 pulses at 86 V/cm for
20 ms with an interpulse interval of 200 ms (Electro Square
Porator ECM 830, BTX). This is a low-dose electroporation
protocol that does not induce damage [13,14,15]. At day 25 post-
inoculation, TA muscles were removed from both control and C26
tumor-bearing mice, weighed, and either snap-frozen in liquid
nitrogen for biochemical analysis or mounted on tongue depres-
sors, embedded in tissue-freezing medium, and frozen in liquid
nitrogen-cooled isopentane for histochemical analysis. Injection of
the NF-kB reporter plasmid was done on the same day as tumor
cell inoculation. Injection of d.n.p65-EGFP was done on day 6
after tumor inoculation.
Plasmids
The expression plasmids used were the following: d.n. IKKa-
EGFP, d.n. IKKb-EGFP, IkBaSR-EGFP, d.n. NIK-GFP, d.n.
p65-EGFP, and d.n. c-Rel-EGFP. The d.n. IKKa-EGFP (K44M)
and d.n. IKKb-EGFP (K44M) expression plasmids encode EGFP
fusion proteins of kinase-dead forms of IKKa and IKKb that we
have described in detail [11]. We also constructed the IkBaSR-
EGFP fusion plasmid that we have described in detail [16]. The
d.n. p65 (313) is a truncated form of p65 missing the C-terminal
transactivation domains and was a gift from D. Guttridge [17]. We
created a d.n. p65-EGFP fusion plasmid by cloning the N-terminal
313 amino acid-coding DNA sequence of p65 into the HindIII-
SalI sites of pEGFP-N1 (313+238=551 a.a.). We verified the
cloning by sequencing the plasmid and tested the dominant
negative function in C2C12 myotubes, in which the d.n. p65-
EGFP was able to block the TNFa activation of an NF-kB
reporter by .90% (Figure S1A). For the creation of a d.n. c-Rel-
EGFP plasmid, we used a mouse c-Rel template, a gift from
IKKb in Cancer Cachexia is NF-kappaB-Independent
PLOS ONE | www.plosone.org 2 January 2014 | Volume 9 | Issue 1 | e87776
T. Gilmore, copying the nucleic acid sequence for the Rel
homology domain of the gene containing a.a. 1-288 (missing the
two N-terminal transactivation domains) and adding restriction
sites to clone the fragment in-frame into the EcoRI-KpnI sites of
pEGFP-N1. The resulting d.n. c-Rel-EGFP insert was checked by
sequencing and functioned as a dominant negative Rel because its
expression reduced NF-kB reporter levels in C2C12 myotubes
(Figure S1B). The d.n. NIK-GFP expression plasmid, a gift from
A. Kumar, encodes a kinase dead form of NIK and EGFP from a
separate cistron [18].
Immunohistochemistry
TA muscle fiber cross-sectional areas of plasmid-transfected
fibers (expressing green fluorescence fusion proteins) were com-
pared to fiber areas in the same fields that did not take up the
plasmid in both tumor-bearing and control mice. As previously
described [11], frozen sections were taken from the mid-belly of
the TA (7.5 mm-thick), mounted on Tissue Tack microscope slides
(Polysciences, Inc, Warrington, PA, USA) and fixed in 4%
paraformaldehyde. Cross sections were washed, blocked in 10%
BSA and incubated with rabbit anti-laminin 1:200 (L9393; Sigma-
Aldrich) in 1% BSA followed by a Texas Red-X goat anti-rabbit
IgG fluorescent dye-conjugated secondary antibody 1:200
(T-6391; Invitrogen). Sections were mounted on a coverslip with
Vectashield mounting medium (Vector Laboratories, Burlingame,
CA, USA). Images were visualized at 20X magnification using an
inverted light microscope (Nikon Eclipse TS 100). All images were
captured with a SPOT RT camera (Diagnostic Instruments,
Sterling Heights, MI, USA). Fiber cross-sectional area was
calculated using the Meta-Morph Imaging System (Universal
Imaging, Glendale, WI, USA). The average number of fibers
measured per muscle was 200.
Isolation of crude nuclear extracts
Crude nuclear extracts from hind limb muscles of 13 to 23 day
C26-inoculated CD2F1 male mice and age matched controls were
isolated according to Kumar and Boriek [19] with some
modifications. All isolation steps and spins were carried out at
4uC using chilled buffers. Flash frozen muscles were suspended at
1 mg muscle weight per 18 ml of buffer (10 mM HEPES [pH 7.9],
10 mM KCl, 3 mM MgCl2, 0.1 mM EDTA [pH 8], 0.1 mM
EGTA, 0.1% Triton X-100, 1 mM dithiothreitol, 0.5 mM
phenylmethylsulfonyl fluoride, and protease inhibitor cocktail)
and immediately homogenized on ice. Homogenized muscles were
incubated on ice for 5 min followed by 20 s of vigorous vortex.
Nuclei were spun at 30006 g for 10 min. The supernatant was
removed and stored at 280uC. Nuclear pellets were washed with
1 mL of modified cytoplasmic extract buffer without Triton X-100
and centrifuged at 30006 g for 3 min. Pellets were resuspended in
4 ml of nuclear extract buffer (20 mM HEPES [pH 7.9], 420 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 25% glycerol, 1 mM
dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, and prote-
ase inhibitor cocktail) per mg of original muscle weight. Re-
suspended nuclear pellets were incubated on ice for 30 min with
15 s of vigorous vortexing every 10 min. Samples were centrifuged
at 16,0006 g for 20 min and nuclear extract (supernatant) was
removed and stored at 280uC.
Electrophoretic mobility shift assay (EMSA)
Protein concentration of crude muscle nuclear extracts was
determined using the Bradford assay (Bio-Rad Protein Assay Dye
Reagent, Bio-Rad Laboratories, Hercules, CA, USA). Double
stranded NF-kB IRDye 700 infrared dye end-labeled oligonucle-
otide, 59-AGTTGAGGGGACTTTCCCAGGC-39 (underline in-
dicates NF-kB binding site), was purchased from LI-COR
Biosciences (Lincoln, NE, USA). Consensus unlabeled competitor
NF-kB oligonucleotide was purchased from Integrated DNA
Technologies, Inc. (Coralville, IA, USA). EMSA binding reaction
was performed using Odyssey EMSA Buffer Kit (LI-COR
Biosciences) with some modifications. Total reaction volume was
prepared in 20 ml. Binding reaction reagents were added to
purified water in the following order: 2 ml of binding buffer
(100 mM Tris, 500 mM KCl, 10 mM DTT; pH 7.5), 2 ml of
25 mM DTT/2.5% Tween-20, 1 mg/ml poly dINdC in 10 mM
Tris, 1 mM EDTA; pH 7.5, 50 fmole NF-kB IRDye 700 infrared
dye end-labeled oligonucleotide, and 15–20 mg nuclear extract. In
reactions with unlabeled NF-kB competitor, unlabeled and labeled
oligonucleotides were mixed prior to addition to the binding
reaction. Binding reactions were gently mixed and incubated for
25 min, at room temperature, in the dark. Prior to loading
samples, 2 ml of Orange Loading Dye (65% w/v sucrose, 10 mM
Tris-HCl pH 7.5, 10 mM EDTA, 0.3% w/v Orange G) was
added to the 20 ml reaction and gently mixed.
DNA-protein complexes were separated from free oligonucle-
otide on non-denaturing 5% Tris-borate-EDTA, PAGE Ready
Gels (Bio-Rad Laboratories, Inc.). Samples were electrophoresed
at 76 V for 2 hours at room temperature in the dark. Protein
bound to labeled oligonucleotide complexes were visualized using
an Odyssey Infrared Imager (LI-COR Biosciences).
NF-kB-dependent reporter activity
At the indicated time points, TA muscles transfected with an
NF-kB-dependent luciferase reporter were harvested and then
homogenized in 1 mL Passive Lysis Buffer (Promega, Madison,
WI) with protease and phosphatase inhibitors (Roche Applied
Science, Indianapolis, IN). Homogenates were centrifuged at
5,0006 g at 4uC for 20 minutes. Supernatant was collected and
mixed with Luciferase Assay Reagent (Promega) according to
manufacturer’s instructions. Luciferase activity was measured by a
TD-20/20 luminometer (Turner Designs, Sunnyvale, CA, USA).
Western blot analysis
Protein concentration of muscle lysates in passive lysis buffer
was determined using the Bradford assay (Bio-Rad Protein Assay
Dye Reagent, Bio-Rad Laboratories, Hercules, CA). Fifty to 75
micrograms of protein was denatured and size fractionated on
4–15% SDS-polyacrylamide gels. Proteins were transferred to an
Immobilon-FL polyvinylidene fluoride membrane (Millipore,
Bedford, PA, USA), blocked in Odyssey blocking buffer (LiCor
Biotechnology, Lincoln, NE, USA) and incubated with the
appropriate primary antibody according to the manufacturer’s
instructions. Antibodies included: anti-IKKa/IKK1 (IMG-5477,
Imgenex, San Diego, CA, USA), IKKb/IKK2 (#2684), NF-kB2
(p100/p52; #4882), and p-IkBa (#9246) (Cell Signaling Tech-
nology, Danvers, MA, USA), IkBa (sc-371), NF-kB p65 (sc-7151),
c-Rel (sc-6363), and NIK (sc-7211) (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Anti-GAPDH (G-9545) was used as a
loading control (Sigma-Aldrich, St. Louis, MO, USA). Alexa Fluor
680 fluorescent dye-conjugated secondary antibody (Invitrogen)
was used for visualization with the Li-Cor Odyssey infrared
imaging system described previously [20].
RNA isolation
Gastrocnemius and plantaris muscles were harvested from
anesthetized control and tumor-bearing mice (25 days post-
inoculation), snap-frozen in liquid nitrogen, and stored at -80uC
until further processing. Total RNA was extracted using Trizol
reagent (Invitrogen, Carlsbad, CA, USA) according to the
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manufacturer’s instructions. The extracted total RNA was further
purified using an RNase-Free DNase I kit (Qiagen, Valencia, CA,
USA) and an RNeasy Mini kit (Qiagen) as previously described
[21]. Extracted RNA was quantitated by UV spectrophotometry
and quality checked by a 1% denaturing agarose gel. Samples
were also verified by Bioanalyzer 2100 analysis and had a minimal
RIN number of 8.0 (Agilent, Palo Alto, CA, USA).
Microarray analysis
For microarray analysis, the RNA samples described above
were sent to the Boston University Medical Center Microarray
Core Facility for amplification, labeling, and hybridization on a
mouse Affymetrix Gene 1.0 ST array (Santa Clara, CA, USA) per
the manufacturer’s instructions to measure the expression of
28,132 well-annotated genes. A total of 6 array images (3 control
muscle samples and 3 C26 muscle samples) were acquired by
GeneChip Scanner 3000 TG and quality assessed by Affymetrix
Expression Console (Santa Clara, CA, USA). Gene expression
signal values were generated by the Expression File Creator
module of the GenePattern platform (Broad Institute, Cambridge,
MA) and robust multi-array analysis algorithm (RMA) was used
for data preprocessing [22]. Brainarray MoGene 1.0 ST custom
CDF file v.13 was used for probe annotation [23]. Both .cel files
and expression values were deposited into MIAME compliant
NCBI Gene Expression Omnibus with accession number:
GSE48363 (link: http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?token= rnupvmqqyocggpk&acc=GSE48363). Differential gene
expression was computed using the Comparative Marker Selection
module in GenePattern which compares mean differences between
control and C26 groups by two-way parametric t-tests. Parameters
used to identify genes that were differentially expressed in muscle
from tumor-bearing mice were: P-value#0.05, q-value#0.05, and
fold change greater than 1.5-fold. The up- or down-regulated gene
lists were uploaded to the DAVID Bioinformatics database for
functional annotation and for gene ontology assignment based on
the biological process of the genes compared to that of mus musculus
genome where the threshold of EASE score (a modified Fisher
Exact P-value) was set at 0.01 and a minimum gene count of 2.
ChIP-sequencing
Gastrocnemius and plantaris muscles were isolated from control
(i.e. non-tumor-bearing) and C26 tumor-bearing mice at day 25
post tumor inoculation. Freshly dissected muscle was minced and
cross-linked in 1% formaldehyde for 15 minutes, quenched with
glycine and then frozen in liquid nitrogen. For each condition (i.e.,
control or C26) plantarflexor muscle from four legs were pooled,
homogenized, and chromatin isolated as we detailed previously
[21]. This material was sonicated to yield chromatin fragments
that were on average 250 bp. An aliquot of sonicated chromatin
was put aside to be used as the input fraction for ChIP-PCR. The
rest of the chromatin was diluted in IP buffer and split into a group
for incubation with the p65 antibody (Santa Cruz SC-372X) and a
group without any primary antibody; this was done for chromatin
from both control and C26 groups. Samples with and without
primary antibody were incubated for 16 hrs at 4uC with constant
low speed mixing and then the antibody-chromatin complexes
were captured with Protein G magnetic beads. The chromatin was
eluted from the beads and crosslinks reversed, followed by
pronase/RNase treatment and precipitation of the DNA. One
tenth of the material was used for PCR for a gene already shown
to have robust p65 binding in order to test the p65 ChIP. Three
different DNA libraries were made: control p65 ChIP, C26 p65
ChIP, and ChIP with no primary antibody. The libraries were
prepared for high throughput sequencing using the Illumina ChIP-
seq Library kit. An aliquot of each library was examined by
acrylamide electrophoresis and Sybr-gold staining to estimate the
quality by size and intensity of the product which appears as a
smear with an average size of 350 bp. The entire procedure for
making the three libraries was repeated a second time with new
muscle samples in order to have two ChIP-seq libraries for each of
the three groups. The libraries were sent to The Whitehead
Institute (Cambridge, MA) where they were cleaned of adapter
dimers using Ampure XL beads. The cleaned libraries were tested
by Bioanalyzer and qPCR quality control was performed in order
to determine how much of each library to use. The libraries were
sequenced using Illumina Solexa sequencing on a GA II
sequencer. The resulting sequences from control and C26 samples
were aligned to the mouse genome (mm9 version) using ELAND.
The sequences were sent to our lab in the ELAND format.
The alignments for the two independent control samples were
pooled and the same was done for the two C26 samples. In each
case this was done by combining the .bam forms of the alignments
on the Galaxy website. The sequences were then evaluated with
the FastQC package of quality control tests, which was obtained as
a standalone program from the Brabaham Institute (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/). After the initial
FastQ analysis two operations were performed on the ChIP-seq
data: 1. we removed pcr duplicates using samtools rmdup via
Galaxy, and 2. again using samtools, we took advantage of the
mapping labels in the ELAND data to isolate only reads mapped
at unique sites in the mouse genome. Sequence reads were 35 or
36 base pairs. The three files of ChIP-seq data were: control p65
ChIP (10.7 million reads), C26 p65 ChIP (11.1 million reads), and
a file representing background sequence reads (8.5 million)
obtained by combining control and C26 sonicated chromatin
which was run through the ChIP without a primary antibody (no
antibody group). These three post-QC sequence .bam files are
available online at: (https://drive.google.com/folderview?id =
0B0Ph0YwXvamQektEaTFkcElSLTQ&usp=sharing) The aligned
sequences were converted to .sam format and then uploaded to the
peak finder program inChIPseeqer [24] with the following parameters:
1. threshold =5, 2. fold change =2 or greater (compared to
background), 3. fragment length =250 bp, 4. peak length at least
100 bp and 5. peak separation at least 100 base pairs. In addition to
identification of control and C26 p65 peaks relative to the background
(no antibody), ChIPseeqer identified the gene region of the p65 binding
peaks (i.e., genomic location of the peaks).
The sets of control and C26 p65 peaks were run on
PeakAnalyzer [25] (http://www.ebi.ac.uk/research/bertone/soft
ware#peakanalyzer) in order to find the gene with the nearest
TSS for each peak. This generates a list of genes with peaks less
than 100 kb from the TSS. The lists were then compared to the
lists of increased and decreased mRNA expression from the
control vs. C26 microarray data by using a perl algorithm located
on a web page developed by Jim Lund at the University of
Kentucky (http://nemates.org/MA/progs/Compare.html).
Positive Control for ChIP
To confirm the correct binding of the p65 antibody we studied
ChIP with PCR for two consecutive highly studied and verified
NF-kB promoter binding sites in the mouse IP-10 (Cxcl10) gene
[26]. This ChIP experiment also used an antibody for p50 (Santa
Cruz SC-1190X). A positive control for ChIP was made with
chromatin from C2C12 myotubes that had been treated for
4 hours with 10 ng/ml of mouse TNFa. We previously showed
that this treatment strongly induced a NF-kB luciferase reporter
and increased IP-10 mRNA levels, both of which are dependent
on p65 [27]. For the test experiment we used methods described in
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our previous work [21]. Briefly, formaldehyde fixed chromatin
from untreated and TNFa-treated C2C12 myotubes was immu-
noprecipitated with p65 antibody, p50 antibody, or no antibody
and the Protein G-captured precipitates were processed to
produce DNA which was tested with PCR using primers that
flank the two consecutive NF-kB sites in the IP-10 gene. In
addition, we also evaluated p65 and p50 binding to the IP-10
promoter using the chromatin from control and C26 muscles.
ChIP-PCR for Fbxo6
ChIP-PCR was performed from muscle tissue fixed, homoge-
nized and sonicated as for ChIP-seq, with the exception that p65
antibody was attached to the Protein G magnetic beads by pre-
incubation(overnight at 4C) before incubation with the chromatin,
and the DNA products were used as template for PCR with
primers flanking target binding site of the Fbxo6 gene, as
determined from ChIP-seq. The target site from the ChIP-seq
was in the first intron of the Fbxo6 gene, 2 kb downstream of the
transcription start site. The sequences of the primers used for the
PCR were agctcgttgatgtggaccat (left primer) and cctcctgcttta
ggctcctt (right primer) and produced a PCR product of 302 bp.
Statistics
An ANOVA or a t-test was used for analysis, depending on the
number of groups being compared. Data are expressed as means
6 SE, and significance was established at P,0.05. Statistics for
microarray data are described in the microarray section.
Results
Characterization of C26 tumor-bearing mice
Characterization of this tumor model in our lab involved the
inoculation of CDF1 mice with C26 tumor cells in PBS/matrigel
(n = 164) or with PBS/matrigel only (n = 142). Mice were
sacrificed at 12, 13, 14, 17, 18, 19, 21, 22, 23, 24, 25, and 26
days post tumor cell inoculation. In severe cachexia (days 23–26
post-inoculation) tumor-bearing mice lost 22.1%60.8% of initial
body mass while the non-tumor controls gained 12.3%60.7% of
initial body mass (Figure S2A). As tumor mass increased tibialis
anterior (TA) muscle mass decreased (Figures S2B). The TA
muscle mass of severely cachectic mice was 40.460.3 mg
compared to 51.160.3 mg for age-matched control mice.
Tumor-bearing mice in severe cachexia had 21468.7 mg of
epididymal fat pad mass while control mice had 465610 mg
(Figure S2C). The spleen mass of tumor-bearing mice was
20564.6 mg compared to 75.560.7 mg in non-tumor-bearing
mice (Figure S2D). Tumor mass increased as a function of time
post-inoculation (Figure S2E).
Effect of dominant negative NF-kB signaling proteins on
muscle fiber atrophy in C26 tumor-bearing mice
The mean fiber cross sectional area from TA muscles of C26
tumor-bearing mice was 35% less than fibers from non-tumor-
bearing control mice (Figure 1A). However, overexpression of
d.n.IKKb-EGFP blocked fiber atrophy by 69%. Plotting the
individual fiber areas from muscles in each group by size vs.
frequency reveals the heterogeneous distribution of muscle fiber
area and shows the leftward shift to smaller fiber size due to cancer
and the blocking of that shift in fiber size in the same muscles
overexpressing d.n.IKKb-EGFP (Figure 1B). Confirmation of
expression of full-length d.n.IKKb-EGFP is illustrated by western
blot (Figure 1C), and examples of muscle sections used for
measurement of fiber area are shown (Figure 1D). Overexpression
of IkBaSR-EGFP blocked C26 tumor-induced fiber atrophy by
Figure 1. Effects of d.n. IKKb-EGFP on muscle fiber cross
sectional area (CSA). (A) Mean tibialis anterior (TA) fiber cross-
sectional area in control and C26 tumor-bearing mice in the presence or
absence of d.n. IKKb-EGFP. Each bar represents mean fiber area from 8
muscles (6 SE). The average number of fibers measured per muscle was
200. (B) Fiber area frequency distribution of all fibers from muscles of
control, C26, and C26 + d.n. IKKb-EGFP groups. (C) Western blots of
lysates from TA muscles injected with the empty vector (EV) or d.n.
IKKb-EGFP plasmid confirms overexpression of the fusion protein. d.n.
IKKb-EGFP is 114 kDa. All samples are from the same immunoblot. (D)
Representative cross sections of TA muscles from control and C26
tumor-bearing mice injected with the d.n. IKKb-EGFP plasmid.
Fluorescent red represents laminin staining (anti-laminin incubation
followed by Texas Red-X fluorescent dye-conjugated secondary
antibody). Fluorescent green cytoplasm represents expression of
transfected d.n. IKKb-EGFP. C = control; * significantly different from
control (P,0.05). { significantly different from C26 fibers not
transfected with d.n. IKKb-EGFP (P,0.05).
doi:10.1371/journal.pone.0087776.g001
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41% (Figure 2A, B). Confirmation of the overexpression of full
length IkBaSR-EGFP is shown by western blot (Figure 2C) and
representative muscle cross-sections from which fiber area was
measured are shown (Figure 2D). Overexpression of d.n.IKKa-
EGFP (Figure 3A–D) and d.n.NIK-GFP (Figure 4A–D) did not
block C26 tumor-induced fiber cross sectional area atrophy. We
have previously shown that overexpression of EGFP alone does
not affect fiber area [16].
Figure 2. Effects of IkBaSR-EGFP on muscle fiber cross sectional
area (CSA). (A) Mean tibialis anterior (TA) fiber cross-sectional area in
control and C26 tumor-bearing mice in the presence or absence of
IkBaSR-EGFP. Each bar represents mean fiber area from 8 muscles
(6 SE). (B) Fiber area frequency distribution of all fibers from muscles of
control, C26, and C26 + IkBaSR-EGFP groups. (C) Western blots of
lysates from TA muscles injected with the empty vector (EV) or IkBaSR-
EGFP plasmid confirms overexpression of the fusion protein. IkBaSR-
EGFP is 64 kDa. All samples are from the same immunoblot. (D)
Representative cross sections of TA muscles from control and C26
tumor-bearing mice injected with the IkBaSR-EGFP plasmid. C =
control. * significantly different from control (P,0.05). { significantly
different from C26 fibers not transfected with IkBaSR-EGFP (P,0.05).
doi:10.1371/journal.pone.0087776.g002
Figure 3. Effects of d.n.IKKa-EGFP on muscle fiber cross
sectional area (CSA). (A) Mean tibialis anterior (TA) fiber cross-
sectional area in control and C26 tumor-bearing mice in the presence or
absence of d.n. IKKa-EGFP. Each bar represents mean fiber area from 8
muscles (6 SE). (B) Fiber area frequency distribution of all fibers from
muscles of control, C26, and C26 + d.n. IKKa-EGFP groups. (C) Western
blots of lysates from TA muscles injected with the empty vector (EV) or
d.n. IKKa-EGFP plasmid confirms overexpression of the fusion protein.
d.n. IKKa-EGFP is 108 kDa. All samples are from the same immunoblot.
(D) Representative cross sections of TA muscles from control and C26
tumor-bearing mice injected with the d.n. IKKa-EGFP plasmid. C =
control. * significantly different from control (P,0.05).
doi:10.1371/journal.pone.0087776.g003
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Effect of dominant negative Rel A or c-Rel on muscle
fiber atrophy in C26 tumor-bearing mice
Overexpression of d.n. p65-EGFP reversed C26 fiber atrophy
by only 20% (Figure 5A–D) and overexpression of d.n. c-Rel-
EGFP did not affect fiber atrophy (Figure 6A–D).
Figure 4. Effects of d.n. NIK on muscle fiber cross sectional area
(CSA). (A) Mean tibialis anterior (TA) fiber cross-sectional area in control
and C26 tumor-bearing mice in the presence or absence of d.n. NIK.
Each bar represents mean fiber area from 8 muscles (6 SE). (B) Fiber
area frequency distribution of all fibers from muscles of control, C26,
and C26 + d.n. NIK groups. (C) Western blots of lysates from TA muscles
injected with the empty vector (EV) or d.n. NIK plasmid confirms
overexpression of the protein. d.n. NIK = 130 kDa. All samples are from
the same immunoblot. (D) Representative cross sections of TA muscles
from control and C26 tumor-bearing mice injected with the d.n. NIK
plasmid (encodes GFP on separate cistron). C = control. * significantly
different from control (P,0.05).
doi:10.1371/journal.pone.0087776.g004
Figure 5. Effects of d.n.p65-EGFP on muscle fiber cross sectional
area (CSA). (A) Mean tibialis anterior (TA) fiber cross-sectional area in
control and C26 tumor-bearing mice in the presence or absence of d.n. p65-
EGFP. Each bar represents mean fiber area from 8 muscles (6 SE). (B) Fiber
area frequency distribution of all fibers from muscles of control, C26, and
C26 + d.n. p65-EGFP groups. (C) Western blots of lysates from TA muscles
injected with the empty vector (EV) or d.n. p65-EGFP plasmid confirms
overexpression of the fusion protein. (D) The d.n. p65(313)-EGFP fusion
protein (313 a.a.+238 a.a. =551 a.a. =63 kDa) is of similar molecular weight
as endogenous mouse whole p65 protein (549 a.a. = 60.2 kDa) and they are
not separable on a 4-15% gradient polyacrylamide gel. All samples are from
the same immunoblot. (E) Representative cross sections of TA muscles from
control and C26 tumor-bearing mice injected with the d.n. p65-EGFP
plasmid. C = control. * significantly different from control (P,0.05).
{ significantly different from C26 fibers not transfected with d.n.p65-EGFP
(P,0.05).
doi:10.1371/journal.pone.0087776.g005
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NF-kB transcription factor binding to a NF-kB
oligonucleotide (gel shift assay)
Gel shift assays were performed using gastrocnemius muscle
nuclear extracts isolated from tumor-bearing mice (13–23-day
post-inoculation) and from age matched controls (12 control
muscles and 14 C26 muscles). Figure 7A shows representative
examples of NF-kB oligonucleotide binding from control and C26
extracts isolated at 23 days post-tumor cell inoculation. The
specificity of protein-DNA binding was determined by addition of
excess unlabeled consensus NF-kB oligonucleotide competitor to
binding reaction. There was no significant difference in the
amount of protein binding due to the tumor regardless of the
number of days after tumor cell inoculation. Measurement of band
intensity was combined for each time point and mean values were
plotted for control vs. C26 mice (Figure 7B).
As a positive control for our method of nuclear extract isolation
and NF-kB gel shift procedures, we performed a gel shift assay in
muscles from control and laminin-alpha2 deficient mice (muscles
from M. Girgenrath). These muscles are characterized by
inflammatory markers including significant mononuclear infiltra-
tion [28] and accordingly we found significant increases in protein
binding (Figure 7C) to the same NF-kB oligonucleotide used for
control vs. cancer mice.
NF-kB-dependent reporter activity in muscles from
control vs. C26 mice
Another assay to determine if NF-kB transcriptional activity was
elevated in muscles from tumor bearing mice was measurement of
the activity of a NF-kB dependent luciferase reporter plasmid
injected into the TA muscle of control and C26 mice. Two time
points post-inoculation were assessed which represented mild and
severe cachexia (12 and 25 days). NF-kB reporter activity in the
TA muscle was not different at either 12 or 25 days indicating that
protein binding and/or post-translational changes to protein
binding of the reporter gene did not increase NF-kB transcrip-
tional activity in cachexia (Figure 7D). We have shown that this
same NF-kB reporter plasmid is strongly activated in mouse hind
limb muscle due to unloading [16,29] and in cultured mouse
myotubes due to treatment with TNFa, IL-1b, IL-1a, or TWEAK
[27,30]. These results showing no activation of the NF-kB reporter
in muscles of mice with C26 tumors are consistent with the gel
shift data.
Expression of p100/p52 in muscles from control vs. C26
mice
When the alternative NF-kB signaling pathway is activated,
p100 is phosphorylated and post-translationally processed to the
p52 NF-kB transcription factor. Western blot showed no change
in the amount of p100 or p52 protein in muscles from control vs.
C26 mice 21 days after tumor cell inoculation (Figure S3). This is
consistent with the lack of effect on cachexia with overexpression
of d.n. NIK and d.n. IKKa which are upstream kinases of the
alternative NF-kB pathway.
Genome-wide mRNA expression microarray
Whole-transcript gene expression arrays were used for mRNA
expression profiling of muscles to compare with ChIP-seq data and
to verify gene expression changes in our hands. Among 28,000
transcripts investigated at day 25 post tumor inoculation, 1,907
genes were differentially expressed in muscles from tumor bearing
mice using q#0.05 and fold change $1.5; 1034 genes were
upregulated and 873 genes were down-regulated (Table S1).
Differentially expressed genes in muscle from tumor bearing mice
were similar to those previously published in severe C26 cancer
cachexia [31] such as upregulation of acute phase response genes,
ubiquitin-proteasomal degradation genes, autophagy genes, key
atrophy genes including MuRF1, atrogin/MAFbx (Fbxo32),
Fbxo30, Fbxo31, cathepsin L, caspase4, Foxo1, Foxo3, Stat3,
Socs3, C/EBPd, Bcl-3, myogenin, Jun B, etc.). Selected transcripts
that were upregulated by 1.5-fold or greater are listed for several
Figure 6. Effects of d.n. c-Rel-EGFP on muscle fiber cross
sectional area (CSA). (A) Mean tibialis anterior (TA) fiber cross-
sectional area in control and C26 tumor-bearing mice in the presence or
absence of d.n. c-Rel-EGFP. Each bar represents mean fiber area from 8
muscles (6 SE). (B) Fiber area frequency distribution of all fibers from
muscles of control, C26, and C26 + d.n. c-Rel-EGFP groups. (C) Western
blots of lysates from TA muscles injected with the empty vector (EV) or
d.n. c-Rel-EGFP plasmid confirms overexpression of the fusion protein.
d.n.c-Rel-EGFP is 60 kDa. All samples are from the same immunoblot.
(D) Representative cross sections of TA muscles from control and C26
tumor-bearing mice injected with the d.n.p65-EGFP plasmid. C =
control. * significantly different from control (P,0.05).
doi:10.1371/journal.pone.0087776.g006
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relevant functional categories; this includes genes involved in
ubiquitin-proteasomal protein degradation, autophagy, other
proteolytic processes, and immune function (Figure 8). To identify
the computationally derived functional processes from the 1,907
differentially expressed genes, we used DAVID’s Functional
Annotation analysis (Table 1). For upregulated genes, 22 GO
terms (biological process) were significantly enriched; 9 were
associated with proteolysis or catabolic processes, 4 were related to
inflammatory processes, and 3 were associated with translation.
The genes found for these GO categories are contained in the
selected upregulated genes shown in the heatmap (Figure 8). For
downregulated genes, 8 GO terms were enriched; these processes
were oxidation reduction, generation of precursor metabolites and
energy, extracellular matrix organization and muscle develop-
ment. The list of up- and down-regulated genes belonging to the
DAVID-identified GO categories are listed in Table S2.
ChIP-Seq of p65 in muscle from control vs. C26 tumor
mice
p65 carries the transactivation domain for itself and for p50 in
the classical heterodimer of NF-kB and so its binding in ChIP is
referred to ‘‘as the hallmark of the active NF-kB complex’’ [32].
We tested our p65 antibody, already validated in the literature
[21,33], for use in our p65 ChIP sequencing libraries by testing it
on a bona fide kB site cluster (two sites separated by 46
nucleotides) in the IP-10 gene. We prepared untreated or
TNFa-treated C2C12 myotube formaldehyde-fixed chromatin
and performed ChIP using no antibody, p65 antibody, or p50
antibody. Binding was evaluated by PCR using primers flanking
the highly conserved verified NF-kB sites in the IP-10 gene
promoter. The results showed marked increases in the PCR
product representing p65 and p50 binding due to TNFa treatment
(Figure 9A).
We then performed ChIP from control and C26 muscles, using
our tested p65 antibody and sequenced the resulting DNA
libraries. We used the quality control analyses of FastQC (Figures
S4-S6) to confirm that our libraries consisted of high quality
uniquely mapped sequences on the mouse genome without
redundancies due to the PCR used in amplification. This
generated 11.16106 and 10.86106 unique alignments for cancer
and control sequences, respectively, on the mouse genome.
ChIPseeqer was used set to the same threshold that we had
employed for Bcl-3 binding to unloaded muscle chromatin [34]
and peaks were identified from the p65 antibody-captured
alignments in control and C26 muscles. Allowing each peak to
be a maximum of 100 kb from its nearest gene TSS, there were
only 100 peaks in the controls and 57 peaks in the C26 samples.
The genes associated with these peaks are presented in Table S3.
For the C26 peaks, 25 were also present in the controls, an
indication of no change in binding for almost 50% of the genes.
Table S3 also shows p65 peak-containing genes that were the same
as genes found to be upregulated or downregulated by at least 1.5
fold in our gene expression arrays. One gene is upregulated in the
C26 group and has a p65 peak in the C26 ChIP-seq but not in the
control, Fbxo6, while 5 genes are downregulated in C26 and
correspond to genes with control p65 peaks that were lost in C26
p65 ChIP-seq, Hdh3, Ibtk, Itgb6, Jph2 and Nav2. The Fbxo6
peak occurred in the first intron of its gene and was verified with
ChIP-PCR as shown in figure S7.
Discussion
The intracellular signaling pathways and transcriptional regu-
lation of muscle wasting due to cancer are just beginning to be
Figure 7. Gel shift assay of NF-kB binding and NF-kB reporter
activity. (A) Bands represent protein-oligonucleotide binding of
gastrocnemius nuclear extracts from control and C26 mice 23 days
post-inoculation. 20 mg of protein incubated with infrared dye labeled
NF-kB oligonucleotide. A lane labeled ‘‘Cold’’ indicates incubation with
200X unlabeled consensus oligonucleotide competitor. Competitor lane
was on same gel as lanes 1 through 4. (B) Signal intensity of bands
representing protein binding to NF-kB oligonucleotide; control mean
value represents 12 independent samples, C26 mean value represents
14 independent samples. Values were combined from 13, 17 and 23
days post-tumor cell inoculation since there was no difference in
binding compared to controls at any time point. (C) As a positive
control for the NF-kB gel shift assay, nuclear extracts isolated from hind
limb muscles of 42 day old Lama22/2 mice compared to aged matched
C57BL/6 wild type (WT) controls are shown. 15 mg of protein incubated
with infrared dye labeled NF-kB oligonucleotide. + indicates incubation
with 150X unlabeled consensus oligonucleotide competitor. Each lane
represents an independent muscle sample. (D) NF-kB-dependent
reporter activity in TA muscles from control and C26 tumor-bearing
mice. NF-kB-dependent luciferase activity in TA muscles at 12 and 25
days after tumor cell inoculation representing mild and severe cachexia.
The number of muscles per group was 6 for the 12-day time point and 8
for the 25-day time point.
doi:10.1371/journal.pone.0087776.g007
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understood. The purpose of this study was to identify NF-kB
signaling proteins, and NF-kB transcription factors functioning in
cancer-induced muscle wasting. The existing literature indicates
the involvement of the NF-kB signaling protein, IkBa, because
LLC tumor-bearing mice overexpressing a super repressor form of
IkBa in skeletal muscle showed a 50% inhibition of muscle fiber
atrophy [5]. In that study, increased binding of the p65 NF-kB
transcription factor was found in muscle from mice with tumors
and this was reversed in the presence of overexpressed IkBaSR.
There is some evidence that NF-kB transcription may be activated
in the type of cancer used in the present study, mouse colon
adenocarcinoma (C26), although NF-kB reporter activity was not
measured [6]. Therefore, we performed in-depth studies to
determine the requirement of the major known NF-kB signaling
proteins and the NF-kB transcription factors in cancer-induced
muscle wasting.
We have now shown that there is a robust, 69% inhibition of
C26-induced muscle wasting when d.n. IKKb is overexpressed,
demonstrating a significant requirement of IKKb. We also
confirmed that an IkBa super repressor can lessen C26-induced
wasting as previously described for LLC-induced wasting [5].
However, IKKa and NIK were not necessary for muscle wasting
indicating that the alternative NF-kB signaling pathway is not
involved in the atrophy process. This was further confirmed by
western blots showing no change in the expression of the p52
NF-kB transcription factor or its precursor protein, p100, in C26
cancer (Figure S3). Classical and alternative NF-kB signaling
pathways have been shown to have divergent roles in muscle in
response to cytokine mediated atrophy and during muscle
development [18,35,36,37], however since we found evidence
for IKKb, and not alternative NF-kB signaling in C26 cachexia,
those divergent actions do not appear to function here.
Surprisingly, neither p65 nor c-Rel was required for C26
atrophy since overexpression of dominant negative forms of these
proteins did not affect fiber size significantly. Consistent with these
findings, gel shift assays showed no change in nuclear protein
binding to NF-kB oligonucleotides and there was no change in
NF-kB-dependent reporter activity in muscles of control vs. C26
tumor bearing mice. Importantly, using genome-wide ChIP-
sequencing, we found almost no NF-kB p65 binding peaks in
genes shown to be upregulated in cancer cachexia as assessed by
our gene expression microarrays. We recently showed that when a
NF-kB transcription factor is unequivocally required for muscle
atrophy, ChIP-seq is a powerful tool that further validates the
requirement of the factor by means of the functional categories of
genes showing transcription factor binding peaks [34]; this was not
the case in C26 cancer for p65 ChIP-seq. An explanation for this
appears in several papers that do find p65 binding sites by ChIP-
seq in which the induction of p65 binding requires strong
inflammatory mediators such as LPS [32] or TNFa [33,38]. We
show in Figure 9A that incubation with TNFa produces IP-10 p65
binding in treated C2C12 cells, however the IP-10 gene does not
Figure 8. Heatmaps of selected upregulated genes in plantar flexor muscles from several functional categories. Data are from muscles
at 25 days post-tumor inoculation (severe cachexia). Red color in the heatmap represents gene upregulation in muscles from C26 mice compared to
the lower control values represented by blue. All genes represented are increased greater than 1.5-fold. Genes involved in: ubiquitin-proteasomal
protein degradation, autophagy, other proteolytic processes (e.g. caspases, cathepsins, and metalloproteases), immune responses (innate and
adaptive), and transcription factor genes are shown. The heatmaps capture most of the upregulated genes in these functional categories but do not
represent a complete list (see Table S2). Each color block represents one pooled sample (control n = 3; C26 n= 3).
doi:10.1371/journal.pone.0087776.g008
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show increased p65 binding due to C26-mediated cachexia
(Figure 9B). Corroborating this, our gene expression array for
control vs. C26 muscle showed that IP-10 mRNA levels were
unchanged (not in Table S1 since there was no change). C26-
induced cachexia does not appear to be mediated by the kind of
inflammatory cytokines that would produce p65 activation.
The lack of binding peaks on genes involved in atrophy
processes could be due to our measurement of binding at only one
time point, severe cachexia. However, at the time of severe
cachexia our microarray data show that the expression of genes
that characterize muscle wasting is ongoing, so at least p65 shows
little direct involvement in activation of genes at this time. In
addition, the overexpression of d.n. p65 or d.n. c-Rel would have
shown a significant blocking of muscle atrophy if these NF-kB
factors were required at an earlier time point in cachexia.
Moreover, NF-kB reporter assays and gel shift assays were done at
several time points, from 12 to 25 days post-tumor cell inoculation,
and at no time was there an activation of the reporter nor a
significant increase in binding to an NF-kB oligonucleotide, unlike
the robust increase we showed in a primary muscle inflammatory
disease (Figure 7C) or in disuse atrophy [39].
Taken together, our data show that although IKKb is necessary
for muscle wasting during cancer cachexia, the changes in gene
expression shown by microarray are not regulated by NF-kB
transcription factors. Another paper that found some evidence of
NF-kB in C26 cachexia also reported that this signaling was not
responsible for the upregulated atrophy genes [6]. The require-
ment for IKKb but not NF-kB transcription factors suggests that
inhibition of IKKb is blocking other cellular processes requiring
this kinase that in turn regulate muscle wasting via transcription
factors other than the NF-kB family members. The possibility that
the IKKs may be activated while not activating NF-kB-regulated
transcription has been demonstrated multiple times over the past
decade [40,41,42,43,44]. This has been referred to as IKK-
dependent, NF-kB-independent signaling [41]. A number of IKK
substrates besides IkBa have been identified, and, other substrates
Table 1. Enriched GO terms in muscle of C26 mice using DAVID functional annotation.
Enriched GO terms in up-regulated genes Count
GO:0006508: proteolysis 87
GO:0009057: macromolecule catabolic process 75
GO:0030163: protein catabolic process 64
GO:0044265: cellular macromolecule catabolic process 63
GO:0051603: proteolysis involved in cellular protein catabolic process 57
GO:0044257: cellular protein catabolic process 57
GO:0010033: response to organic substance 53
GO:0006952: defense response 52
GO:0043632: modification-dependent macromolecule catabolic process 52
GO:0019941: modification-dependent protein catabolic process 52
GO:0006396: RNA processing 48
GO:0009611: response to wounding 39
GO:0006954: inflammatory response 32
GO:0022613: ribonucleoprotein complex biogenesis 28
GO:0042254: ribosome biogenesis 26
GO:0006511: ubiquitin-dependent protein catabolic process 26
GO:0009725: response to hormone stimulus 24
GO:0045087: innate immune response 19
GO:0043434: response to peptide hormone stimulus 18
GO:0002526: acute inflammatory response 17
GO:0009894: regulation of catabolic process 12
GO:0008286: insulin receptor signaling pathway 10
Enriched GO terms in down-regulated genes Count
GO:0055114: oxidation reduction 61
GO:0006091: generation of precursor metabolites and energy 36
GO:0043062: extracellular structure organization 24
GO:0030198: extracellular matrix organization 19
GO:0014706: striated muscle tissue development 19
GO:0060537: muscle tissue development 19
GO:0022900: electron transport chain 18
GO:0030199: collagen fibril organization 8
Count denotes the number of up/down-regulated genes associated with each GO term.
doi:10.1371/journal.pone.0087776.t001
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also exist for IkBa besides the Rel transcription factors [40]. We
have recently reviewed this literature in detail [45]. The process of
muscle wasting due to C26 cancer appears to be another example
of IKKb signaling that is independent of NF-kB transcription. As
further evidence that IKKb is not phosphorylating IkBa, levels of
endogenous IkBa and IkBa phosphorylation are unchanged at
either 10 or 24 days after tumor inoculation (Figure S8).
Recently, other transcription factors have been shown to play a
role in cancer cachexia. C/EBPb is required for LLC-induced
muscle wasting as demonstrated using C/EBPb knockout mice
[46]. Foxo transcription factors have been shown to block LLC-
induced muscle wasting [47] and C26 wasting (A. Judge,
manuscript in review). Inhibition of Stat3 blocked C26-induced
atrophy using several experimental approaches [48] but it is not
known if Stat3 is required for LLC-induced wasting. The
observation that cancer-induced muscle wasting is associated with
increased p65 binding to an oligonucleotide in an ELISA format
may be specific to LLC cancer [5] since none of our assays show
p65 to be required for C26 cancer wasting.
In conclusion, our data show for the first time that IKKb is
required for C26 cancer-induced muscle wasting because inhibi-
tion of IKKb blocks fiber atrophy by 69%. Also we show that the
alternative (non-canonical) NF-kB signaling pathway involving
IKKa and NIK is not required for muscle wasting due to C26
tumors. Interestingly, we find that NF-kB transcription is not
driving the muscle wasting process as evidenced by a lack of an
effect on atrophy due to genetic inhibition of the Rel proteins (p65
and c-Rel) containing transactivation domains, the lack of
increased NF-kB protein binding in gel shift and reporter assays,
and the lack of atrophy target gene binding of the prototypical Rel
transcription factor p65 in genome-wide ChIP-seq experiments.
Further studies on the role of Stat3 and FoxO in C26-induced
wasting are promising areas of investigation, while the identifica-
tion of their target genes using ChIP-seq is a logical next step in
understanding the transcriptional control of muscle wasting. The
downstream target(s) of IKKb is also a prime avenue of research in
order to further understand the cellular signaling underlying
muscle wasting due to colon adenocarcinoma.
Supporting Information
Figure S1 Verification of the inhibiting effect of the
dominant negative forms of p65 and c-Rel. (A) A test of d.n.
p65-EGFP by treatment of myotubes for 4 hours with 10 ng/ml
mouse TNFa. c-Rel-mediated NF-kB activity does not respond to
TNFa in C2C12 cells, but the resting level of NF-kB activity is
determined in part by c-Rel as shown in B. (B) C2C12 cells
transfected with a NF-kB reporter plus control (pEGFP), d. n. p65-
EGFP fusion plasmid, or d.n. c-Rel-EGFP fusion plasmid.
(TIF)
Figure S2 Characterization of cachexia in C26 tumor
bearing mice. (A) Body mass change as a function of tumor size.
Each value for tumor mice has a corresponding value for age-
matched control mice. (B) TA muscle mass as a function of tumor
size. Values for age-matched control mice are plotted for
comparison. (C) Epididymal fat mass as a function of tumor size.
Values for age-matched control mice are plotted for comparison.
(D) The correlation between spleen size and tumor mass. (E)
Relationship between tumor size and time of inoculation.
(TIF)
Figure S3 Western blot of p100 and p52 from TA muscle
of control and C26 mice. Muscles were from mice 21 days post
C26 inoculation. 70 mg of lysate loaded per lane and blot
incubated with p100/p52 (NF-kB2) antibody. Each lane repre-
sents an independent muscle sample. Extract from Hela cells used
as positive control.
(TIF)
Figure S4 FastQC printout for bam format of C26 p65
ChIP-seq. FastQC evaluates the ChIP-seq alignment data on 11
criteria. The output in this case passed all tests and was then used
for peak analysis.
(PDF)
Figure S5 FastQC printout for bam format of Control
p65 ChIP-seq. The sequences passed all tests and were taken for
peak analysis.
(PDF)
Figure 9. ChIP PCR to validate the p65 antibody and comparison of p65 binding in cancer cachexia vs. a classic inflammatory
system. (A) Chromatin was prepared from C2C12 myotubes that had been untreated or treated with 10 ng/ml mouse TNF for 4 hours and from (B)
gastrocnemius/plantaris muscles of mice with and without 25 days of C26 tumor-induced cachexia. Chromatin was sonicated and
immunoprecipitated without antibody or with the same antibody to p65 used for ChIP-seq or with a p50 antibody. Captured precipitates were
used to prepare DNA template evaluated by PCR with primers that flank two closely spaced validated NF-kB sites in the IP-10 promoter. PCR products
are shown on acrylamide gels, stained with Sybr gold. Standards are 100 bp ladder. Input lanes are PCR products using the same primers on
chromatin taken before ChIP.
doi:10.1371/journal.pone.0087776.g009
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Figure S6 FastQC printout for bam format of no
antibody ChIP-seq (background). The background align-
ments passed all tests and were used as the input reference for the
ChIPseeqer program.
(PDF)
Figure S7 ChIP-PCR of the p65 binding site in the Fbxo6
gene. Chromatin prepared exactly as that for ChIP-seq was
incubated with no antibody on Protein G beads or the p65
antibody (SC-372X) which had been attached to Protein G
magnetic beads and then the material was washed and prepared as
for the ChIP-seq except that instead of making a sequencing
library with the resulting DNAs, PCR was run on the DNA as
described in the Methods section. The results are presented from a
10% acrylamide TBE gel, stained with Sybr Gold. The expected
band is 302 bp and the lanes are from left to right: S the 100 bp
standards; the no antibody lanes, Control and C26; the p65 lanes
Control and C26 and the input lanes, Control and C26. By simple
densitometry, the intensity of the C26 p65 band is 1.8 fold greater
than that for the Control p65 band.
(TIF)
Figure S8 Western blots of phospho-IkBa and IkBa in
control and C26 muscle. (A) Gastrocnemius muscle extracts
from mice 10 days post inoculation. (B) Gastrocnemius muscle
extracts from mice 24 days post inoculation. 60 mg protein loaded
per lane. Each lane represents an independent muscle sample.
There were no changes in p-IkBa or IkBa expression due to either
time point of cachexia.
(TIF)
Table S1 Differentially expressed genes due to cancer
(q,0.05, p,0.05, $1.5-fold change).
(XLSX)
Table S2 Cachexia-induced up- and down-regulated
genes ($1.5-fold) belonging to DAVID-identified GO
categories shown in Table 1.
(XLSX)
Table S3 The genes with p65 ChIP-seq peaks from
control (no tumor) and C26 muscle. From left to right the
columns are: control p65, with reference to no antibody
background alignments; C26 p65, with reference to no antibody
background alignments; Intersect, the genes in common between
control and C26; Control/Array+, the genes from Control ChIP-
seq in common with .1.5 fold upregulated genes from the gene
expression microarray; Control/Array-, the genes from the
Control ChIP-seq in common with .1.5 fold downregulated
genes from the gene expression microarray; C26/Array+, the
genes from C26 ChIP-seq in common with .1.5 fold upregulated
genes from the gene expression microarray; C26/Array-, the genes
from the C26 ChIP-seq in common with .1.5 fold downregulated
genes from the gene expression microarray.
(DOCX)
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